Following on this result and noting that IL-6 levels are elevated in the sera of SSc patients and are highly correlated with skin damage, led to the suggestion of a clinical trial for tocilizumab, an IL-6 receptor blocker22. This evidence concerns the gene IL6 and systemic sclerosis.